

Brukinsa

Qatar · access guide

How to access Brukinsa for chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenstrom macroglobulinaemia, marginal zone lymphoma, and follicular lymphoma from Qatar: 2026 pathway via NCCCR Hamad Medical Corporation and Qatar haematology supply

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Qatar's adult haematology and lymphoma reference is the National Center for Cancer Care and Research (NCCCR) at Hamad Medical Corporation in Doha. NCCCR is the country's adult oncology and haematology referral centre, with multidisciplinary tumour board coverage for B-cell malignancies, transplant evaluation, and a developing CD19 CAR-T cell therapy programme. Sidra Medicine is paediatric-only and is not the relevant centre for adult Brukinsa. The private sector adds Al-Ahli Hospital, Doha Clinic, Aspetar (for sport-related rheumatology, not the right setting for haematological malignancy), and the regional MENA chain providers. Brukinsa (zanubrutinib, BeiGene) is the second-generation, more selective BTK inhibitor on the prescribing physician's shortlist for adult patients with CLL, SLL, MCL, WM, MZL, or FL (in combination with obinutuzumab) where chronic BTK inhibition is the preferred long-term strategy.

This page explains how the pathway works in 2026 for a Qatar-resident adult: who qualifies, where the prescribing haematologist conversation happens, how Brukinsa is dispensed within Qatar MOPH-regulated channels, what insurance and HMC funding pre-authorisation looks like, what the realistic annual cost band is in QAR, what to monitor across the first 6 months, and how the years-long treatment course fits into family life.

Why Brukinsa, and why now

Brukinsa is zanubrutinib, an oral, selective, second-generation Bruton tyrosine kinase inhibitor developed by BeiGene Ltd. The mechanism is covalent inhibition of BTK, the kinase that sits downstream of the B-cell receptor and that is essential to the survival of malignant B-cells in CLL, MCL, WM, MZL, and FL. What separates Brukinsa from the first-generation BTK inhibitor ibrutinib (Imbruvica) is selectivity: ibrutinib hits a wider range of off-target kinases, which translates into a higher rate of atrial fibrillation, bleeding, hypertension, and infection over the years of chronic therapy. Brukinsa's narrower kinase footprint translated into the ALPINE head-to-head trial in relapsed or refractory CLL: lower rate of atrial fibrillation, lower bleeding signal, and superior progression-free survival versus ibrutinib at 30 months.

The FDA approved Brukinsa for mantle cell lymphoma in November 2019 (accelerated), Waldenstrom macroglobulinaemia in August 2021, marginal zone lymphoma in September 2021, chronic lymphocytic leukaemia and small lymphocytic lymphoma in January 2023, and follicular lymphoma in combination with obinutuzumab in March 2024. Qatar MOPH registration is verified at intake.

Reserve Meds does not promote one BTK inhibitor over another.

What Brukinsa is, in plain language

Brukinsa is an oral capsule. There is no infusion centre, no inpatient stay. The patient takes the capsules at home. The standard dose is 160 mg twice daily (BID), or 320 mg once daily (QD); both schedules are FDA-approved and produce equivalent steady-state exposure. The capsules can be taken with or without food.

This is not a short course. Brukinsa is taken continuously for as long as it controls the disease.

Eligibility at a Qatar haematologist clinic

For Qatar-resident adult patients, NCCCR and the wider haematology network apply the FDA and EMA criteria with local adaptation:

1. Confirmed indication. CLL/SLL, MCL (typically after at least one prior line for FDA-accelerated label), WM, MZL after anti-CD20 therapy, or FL after two prior lines (in combination with obinutuzumab). Diagnosis confirmed by flow cytometry, immunohistochemistry, and where indicated FISH, IGHV mutation status, TP53 status, and bone marrow biopsy.
2. Treatment history. First-line eligible in CLL and WM; later-line eligible in MCL, MZL, FL.
3. Adult (18 years or older). No paediatric label for Brukinsa; paediatric haematology cases are managed at Sidra Medicine and would use a different therapeutic strategy.
4. Hepatitis B screen. HBsAg and anti-HBc both checked. HBV-positive patients need hepatology co-management and antiviral prophylaxis before starting.
5. HIV screen.
6. Pregnancy planning for women of childbearing potential; effective contraception required.
7. Drug-interaction review. Strong CYP3A inhibitors require dose reduction; strong inducers should be avoided. Concomitant antiplatelet or anticoagulant therapy should be minimised where possible.
8. Second primary malignancy counselling. Annual dermatology surveillance is recommended.

The Qatar prescribing and supply picture, plainly

Brukinsa Qatar MOPH registration status is verified at intake. BeiGene's MENA commercial supply runs through regional distributors. The pathway is:

1. **Prescribing haematologist:** a board-certified haematology or haematology-oncology consultant at NCCCR HMC Doha (the adult reference). Multidisciplinary tumour board discussion is standard for first-line and later-line decisions. Sidra Medicine is not the relevant centre for adult B-cell malignancies. Transplant evaluation and CD19 CAR-T cell therapy candidacy are assessed at NCCCR or referred cross-border to KFSHRC Riyadh, Cleveland Clinic Abu Dhabi, or KHCC Amman. 2. **Pharmacy dispensing:** HMC hospital pharmacy at NCCCR for the first 1 to 3 months of supply; MOPH-licensed community pharmacy thereafter where available (Brukinsa is shelf-stable at room temperature). Monthly or 3-monthly dispensing rhythm is typical. 3. **Insurance and HMC funding pre-authorization:** HMC funding for Qatari nationals covers Brukinsa for documented indications through the specialty drug formulary. Private insurers operating in Qatar review on a case-by-case basis with prior-line documentation for MCL, MZL, and FL. 4. **Baseline labs:** complete blood count, comprehensive metabolic panel, hepatitis B serology, HIV, ECG, blood pressure measurement. 5. **Ongoing monitoring:** NCCCR haematology follow-up monthly for the first 3 months, then quarterly. CBC at each visit. Blood pressure check at every visit. Annual dermatology surveillance.

Cost band and insurance positioning

US list price for Brukinsa is approximately USD 14,000 to 16,500 per month at WAC. Annual cash list price is approximately USD 165,000 to 200,000.

At 2026 indicative cross rates, the QAR-equivalent annual cost band is approximately QAR 600,000 to 730,000 at list price. HMC funding for Qatari nationals substantially reduces out-of-pocket exposure for eligible patients; commercial insurance reduces exposure for insured residents.

What to expect on Brukinsa, week-by-week

Week 1 to 4: First weeks on Brukinsa. CBC, blood pressure, and side-effect check at the first NCCCR follow-up. Common early side effects: fatigue, bruising, mild infection.

Week 4 to 12: Response assessment begins. CLL and WM patients may show transient lymphocytosis (on-target, not progression). MCL, MZL, FL: imaging response at week 12.

Month 3 to 6: Continued tolerability check. Watch for atrial fibrillation, hypertension, infections, bruising or bleeding.

Month 6 and beyond: Quarterly NCCCR follow-up. Annual dermatology surveillance.

When Brukinsa is the wrong drug

For a Qatar adult patient with active hepatitis B not yet under hepatology management, severe hepatic impairment, active serious bleeding, chronic strong CYP3A inhibitor therapy, during pregnancy, or a strong preference for fixed-duration therapy, the operational pathway shifts:

- **Venetoclax-based regimens (Venclexta with obinutuzumab or rituximab):** fixed-duration BCL-2 inhibition in CLL. - **Acalabrutinib (Calquence) or pirtobrutinib (Jaypirca):** alternative selective or non-covalent BTK inhibitors. - **Chemoimmunotherapy (FCR, BR):** for selected fit younger patients with mutated IGHV CLL. - **CD19 CAR-T cell therapy or bispecific antibodies:** for relapsed or refractory disease after multiple lines (cross-border to KFSHRC Riyadh, Cleveland Clinic Abu Dhabi, or KHCC Amman where NCCCR refers).

Reserve Meds does not promote one BTK inhibitor over another.

What Reserve Meds does on this case

We are a US-based concierge coordinator. On a Qatar Brukinsa case we build the documentation pack with the treating haematologist's office at NCCCR, confirm MOPH registration status and the HMC dispensing pathway, run the HMC funding or commercial insurance pre-authorisation conversation, coordinate supply logistics, organise baseline screening, and stay with the case through the first year of dosing with handoff to the local haematologist. Clinical decisions remain with your treating haematologist.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com